[HTLV-1-associated myelopathy]

Area of Science:

• Virology
• Neuroimmunology
• Oncology

Context:

• Human T-cell leukemia virus type 1 (HTLV-1) infection leads to severe conditions like HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATL).
• HAM/TSP is a debilitating, progressive neurological disorder affecting the spinal cord, impacting mobility and quality of life for a subset of HTLV-1 infected individuals.
• Understanding the molecular pathogenesis of HTLV-1 is crucial for developing effective treatments for associated diseases.

Purpose:

• To provide an updated review of novel drug development for HAM/TSP.
• To outline current therapeutic algorithms for managing HAM/TSP.
• To integrate recent findings in molecular pathogenesis and biomarkers into treatment strategies for HAM/TSP.

Summary:

• This review synthesizes recent advancements in understanding the molecular mechanisms underlying HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
• It details emerging therapeutic agents and revised treatment protocols for HAM/TSP, informed by new molecular insights and identified biomarkers.
• The focus is on translating cutting-edge research into actionable clinical strategies for this intractable neurodegenerative disease.

Impact:

• This review offers clinicians and researchers the latest information on managing HAM/TSP, potentially improving patient outcomes.
• It highlights the importance of molecular pathogenesis and biomarkers in guiding therapeutic decisions for HTLV-1 infection.
• The findings contribute to the development of more targeted and effective treatments for HAM/TSP and related HTLV-1 associated conditions.